# Eltrombopag vs. rhTPO to Increase Platelet Level After HSCT

> **NCT03515096** · PHASE3 · COMPLETED · sponsor: **Shenzhen Second People's Hospital** · enrollment: 98 (actual)

## Conditions studied

- Eltrombopag
- Hematopoietic Stem Cell Transplantation
- Thrombocytopenia

## Interventions

- **DRUG:** Eltrombopag
- **DRUG:** rhTPO

## Key facts

- **NCT ID:** NCT03515096
- **Lead sponsor:** Shenzhen Second People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-01
- **Primary completion:** 2021-08-02
- **Final completion:** 2022-07-01
- **Target enrollment:** 98 (ACTUAL)
- **Last updated:** 2022-07-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03515096

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03515096, "Eltrombopag vs. rhTPO to Increase Platelet Level After HSCT". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03515096. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*